Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch
'"/>





Page: 1 2

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 28, 2011 Tengion, Inc. (Nasdaq: TNGN ) ... to its Board of Directors. Mr. Flora brings to Tengion ... wound healing and surgical device businesses.  He most recently served ... Tengion also announced today that Gary Kurtzman, ...
... SOUTH SAN FRANCISCO, Calif., Sept. 28, 2011 Onyx ... that it has completed the New Drug Application (NDA) ... under the accelerated approval process for carfilzomib, a next ... with relapsed and refractory multiple myeloma. In addition, Onyx ...
Cached Medicine Technology:Tengion Appoints Scott Flora to Board of Directors 2Tengion Appoints Scott Flora to Board of Directors 3Tengion Appoints Scott Flora to Board of Directors 4Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 3Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 4
(Date:8/21/2014)... 2014Popular fiction that normalizes and glamorizes violence against women, ... associated with a greater risk of potentially harmful health ... study are presented in the article " Fiction or ... Adolescent and Young Adult Females ," published in ... Mary Ann Liebert, Inc., publishers . The article ...
(Date:8/21/2014)... Individuals with schizophrenia often have trouble engaging in ... new study from San Francisco State University suggests the ... of effort required to complete tasks. , The research, ... Journal of Abnormal Psychology , can assist health ... and help those patients function normally by breaking up ...
(Date:8/21/2014)... Entries are now open for the ... national awards program totally dedicated to recognizing excellence in ... leadership. The entry deadline is Oct. 17. , The ... the first and only national magazine entirely devoted to ... “We launched the HREI Insights Awards program last year ...
(Date:8/21/2014)... 2014 Recently it came to the ... located in Massachusetts has made public claims on August ... patient verification system in the Massachusetts cannabis industry. While ... our growing and compassionate industry we must set the ... are inaccurate. , MarijuanaDoctors.com has actually been providing ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... respiratory syncytial virus (RSV), a leading cause of pneumonia in ... in being able to treat human RSV infections -- the ... to influenza virus," said study author Dr. John DeVincenzo, a ... Medicine in Memphis. "There is no current treatment ...
Breaking Medicine News(10 mins):Health News:Women's health and Fifty Shades: Increased risks for young adult readers? 2Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3
... who undergo heart surgery fare better if they receive ... ,Investigators say that children who received reconstituted ... cells and plasma -- tended to accumulate less fluid, ... the study, researchers compared results for 200 infants who ...
... the brain using the CyberKnife frameless radiosurgery can successfully ... CyberKnife is a non-invasive robotic radiosurgical device that can ... uses a robotic arm, controlled by a computer, that ... tumor site. ,During the study researchers examined ...
... are obese when they are diagnosed with early-stage breast cancer ... women of normal weight.// ,Studies in the past have ... development, and has also shown to have contradictory results about ... latest study researchers say, they have demonstrated a significant association ...
... is an often disabling condition that affects primarily women. ... cannot be overcome with rest and often worsens with ... and there are no diagnostic tests or cures. A ... are at increased risk for developing chronic fatigue later ...
... in restoring sudden onset hearing loss. Researchers say sudden hearing ... of the sudden hearing loss can be identified in only ... includes viral and bacterial diseases, and metabolic, neurologic and immunologic ... which case there is no known cause. ,Previous research ...
... that affects more than 80 percent of teenagers and up ... cited // as a source of acne, these claims have ... this study. Each participant had at least one academic examination ... sources of stress for students. Stress levels were recorded using ...
Cached Medicine News:
...
...
Bimanual I&A Cannulas. Curved 45 with a .51mm open-end irrigation port. Facilitates removal of cortical debris between 10-2 o'clock. .80mm x 17.0mm...
...
Medicine Products: